"dyrupeg-biosimilar"

Aurobindo Pharma said its subsidiary CuraTeQ Biologics has received a Notice of Compliance from Health Canada for its biosimilar Dyrupeg, used to treat cancer patients with low neutrophil levels, following a successful regulatory review